Rockefeller Capital Management’s Anika Therapeutics ANIK Stock Holding History

Rockefeller Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.4K	Sell	506 -566	-53%	-$8.39K	﹤0.01%	4126
2026 Q1	$15.5K	Buy	1,072 +858	+401%	+$9.96K	﹤0.01%	3808
2025 Q4	$2.06K	Buy	+214	New	+$2.05K	﹤0.01%	4309
2023 Q1	–	Sell	-13	Closed	–	–	2061
2022 Q4	$0	Hold	13	–	–	﹤0.01%	3831
2022 Q3	$0	Sell	13 -18	-58%	-$414	﹤0.01%	3861
2022 Q2	$0	Buy	+31	New	+$692	﹤0.01%	4085
2020 Q2	–	Sell	-1,000	Closed	-$29K	–	2569
2020 Q1	$29K	Buy	+1,000	New	+$40.5K	﹤0.01%	1395
2019 Q4	–	Sell	-216	Closed	-$12K	–	2039
2019 Q3	$12K	Hold	216	–	–	﹤0.01%	1359
2019 Q2	$9K	Buy	+216	New	+$7.88K	﹤0.01%	1262

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Rockefeller Capital Management's ANIK Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Anika Therapeutics (ANIK) stake by 53% in Q2 2026, selling an estimated $8.39K and leaving 506 shares worth $7.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4126.

Rockefeller Capital Management first reported a position in ANIK in Q2 2019 and has held it in 9 quarters since. The position peaked at $29K in Q1 2020. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

Rockefeller Capital Management held 506 shares of Anika Therapeutics worth $7.4K as of Q2 2026.
Rockefeller Capital Management sold 566 Anika Therapeutics shares in Q2 2026, an estimated $8.39K.
Anika Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4126 holding.
Rockefeller Capital Management first reported a position in Anika Therapeutics in Q2 2019 and has held it in 9 quarters since.
Rockefeller Capital Management's Anika Therapeutics position peaked at $29K in Q1 2020.
133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.